QUEEN ELIZABETH HOSPITAL RES F has a total of 26 patent applications. Its first patent ever was published in 2003. It filed its patents most often in Australia, Canada and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals and biotechnology are HOFFMAN LA ROCHE LTD, CHILDREN S MEDICAL RES INST and OVITA LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 4 | |
#2 | Canada | 4 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | United States | 4 | |
#5 | WIPO (World Intellectual Property Organization) | 4 | |
#6 | Brazil | 1 | |
#7 | China | 1 | |
#8 | Republic of Korea | 1 | |
#9 | Mexico | 1 | |
#10 | New Zealand | 1 | |
#11 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Koblar Simon | 8 |
#2 | Hamilton-Bruce Monica Anne | 8 |
#3 | Jannes Jim | 8 |
#4 | Stephenson Sally-Anne | 7 |
#5 | Krishnan Ravi | 7 |
#6 | Collin Peter D | 2 |
#7 | Stephenson Sally Anne | 1 |
#8 | Ravi Krishnan | 1 |
Publication | Filing date | Title |
---|---|---|
US2008241824A1 | Mutation Associated With Lacunar Strokes | |
US2005143463A1 | Method of inhibiting angiogenesis | |
BR0314369A | Methods for inhibiting cell growth, for inducing cell death of a cancer cell, for treating or preventing cancer in an individual, and for identifying an agent that inhibits cancerous growth of a purified ephb4 cell, agent, and antibody. | |
AU2003902928A0 | Ex vivo treatment of dendritic cells | |
EP1531804A1 | Method of inhibiting angiogenesis | |
WO03092672A1 | Method of inhibiting rejection of transplanted material | |
AU2003221627A1 | Method of inhibiting angiogenesis | |
AU2003227120A1 | Method of inhibiting rejection of transplanted material | |
AU2003900961A0 | Method of inhibiting rejection of transplanted material |